



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stefan JAROCH et al.

Serial No.: 09/787,848

Group Art Unit: 1625

Filed: March 23, 2001

Examiner: Robinson

For: AMINOALKYL-3, 4-DIHYDROQUINOLINE DERIVATIVES AS NO-SYNTHASE INHIBITORS

RECEIVED  
MAR 12 2003  
TECH CENTER 1600/2900  
#17  
Eugene  
3-19-03

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §§ 1.56, 1.97 and 1.98**

Assistant Commissioner for Patents  
Washington, D. C. 20231

Sir:

**CITED MATERIALS**

Applicant(s) hereby disclose the information listed in the attached form PTO-1449.

- ☐ Copies of materials listed but not attached were cited in parent application Serial No. \_\_\_\_; see 37 C.F.R. § 1.98(d).
- ☐ Copies of materials listed but not attached were cited in an International Search Report dated \_\_\_\_; receipt of the International Search Report and copies of references was confirmed by the PCT International Division of the U.S. PTO in the Notice of Acceptance mailed \_\_\_\_.
- ☒ Copies of materials listed and attached were cited in a communication from a foreign patent office in a counterpart foreign application.

**FEES**

- ☒ A fee is required for this Information Disclosure Statement:
  - ☒ This Information Disclosure Statement is being filed after a first action on the merits but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311 or an action that closes prosecution, and is accompanied by the fee set forth in §1.17(p).
  - ☐ This Information Disclosure Statement is being filed after the mailing date of a final rejection or a notice of allowance under § 1.311 or an action that closes prosecution, but before the payment of the issue fee, and is accompanied by the fee set forth in § 1.17(p) and a certification below.


### CERTIFICATION

- ☐ Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the undersigned, having made reasonable inquiry, no such item was known to any individual designated in 37 CFR § 1.56(c), more than three months prior to the filing of this statement.

### DEPOSIT ACCOUNT

If a fee is due, attached is a check in the amount of \$\_\_\_\_\_. However, the Commissioner is hereby authorized to charge fees under 37 CFR § 1.16 and § 1.17 which may be required to facilitate this filing, or credit any overpayment to Deposit Account #13-3402, two copies of this paper are attached for this purpose.

Respectfully submitted,



---

Harry B. Shubin, Reg. No. 32,004  
Attorney/Agent for Applicants

MILLEN, WHITE, ZELANO  
& BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Blvd. Suite 1400  
Arlington, Virginia 22201  
Telephone: (703) 243-6333  
Facsimile: (703) 243-6410

Attorney Docket No.: SCH-1707

Date: March 10, 2003  
CH:pdr



DEUTSCHES  
PATENT- UND  
MARKENAMT

⑫ **Offenlegungsschrift**  
⑩ **DE 198 45 830 A 1**

⑤ Int. Cl. 7:  
**C 07 D 221/06**  
C 07 D 221/16  
C 07 D 221/18  
A 61 K 31/47

⑪ Aktenzeichen: 198 45 830.4  
⑫ Anmeldetag: 24. 9. 1998  
⑬ Offenlegungstag: 30. 3. 2000

31. MRZ 2000

DE 198 45 830 A 1

⑭ Anmelder:  
Schering AG, 13353 Berlin, DE

⑮ Erfinder:  
Jaroch, Stefan, Dr., 10625 Berlin, DE; Rehwinkel,  
Hartmut, Dr., 12051 Berlin, DE; Hölscher, Peter, Dr.,  
10559 Berlin, DE; Sülzle, Detlev, Dr., 10589 Berlin,  
DE; Hillmann, Margrit, Dr., 13437 Berlin, DE; Burton,  
Gerardine Anne, Dr., 13591 Berlin, DE; McDougall  
McDonald, Fiona, Dr., 14055 Berlin, DE

⑯ Für die Beurteilung der Patentfähigkeit in Betracht  
zu ziehende Druckschriften:


DE 195 38 088 A1  
WO 97 36 871 A1  
WO 97 09 982 A1  
WO 96 14 844 A1

POESCHE, W.H.: Dibenzo c,h]cinnoline Oxides. In:  
J. Chem. Soc. (C), 1966, S.890-893;  
KEENE, B.R.T., TISSINGTON, P.: Studies in the  
Phenanthridine Series: Preparation of Some  
Methylphenanthridines and Amino-derivatives.  
In: J. Chem. Soc., 1965, S.3032-3037;  
WEBBER, Keith, R., et.al.: Substituted  
2-Iminopiperidines as Inhibitors of Human  
Oxide Synthase Isoforms. In: J. Med. Chem.,  
1998, 41, S.96-101;  
Chemical Abstracts:  
Vol.105, 1986, Ref. 190873u;  
Vol. 94, 1981, Ref. 121256n;  
Registry-Datenbankausdruck RN 189577-91-1;

Die folgenden Angaben sind den vom Anmelder eingereichten Unterlagen entnommen

⑰ Aminoalkyl-3,4-dihydrochinolin-Derivate und ihre Verwendung in Arzneimitteln

⑱ Es werden Verbindungen der Formel I, deren tautome-  
re und isomere Formen und Salze



(I)

beschrieben, sowie das Verfahren zu deren Herstellung  
und deren Verwendung in Arzneimitteln.